Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a m...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/9359086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549730671919104 |
|---|---|
| author | Kirsten C. Webb Magdalena Harasimowicz Monica Janeczek Jodi Speiser James Swan Rebecca Tung |
| author_facet | Kirsten C. Webb Magdalena Harasimowicz Monica Janeczek Jodi Speiser James Swan Rebecca Tung |
| author_sort | Kirsten C. Webb |
| collection | DOAJ |
| description | Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a morbilliform eruption, skin exfoliation, and skin irritation, pigmentary abnormalities have also been observed, albeit much more rarely. We present the case of a 72-year-old South Asian male with CML who presented with new-onset hypopigmentation of his face and scalp three years after a dose increase of dasatinib therapy, in the setting of newly discovered borderline hypovitaminosis D. Dasatinib and the other TKIs are believed to induce dyschromias via modulation of the c-kit receptor and its associated signaling pathway, which is involved in melanocyte survival, proliferation, and migration. |
| format | Article |
| id | doaj-art-8e12fa0e610149fb93d1d7e6520395bb |
| institution | Kabale University |
| issn | 2090-6463 2090-6471 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dermatological Medicine |
| spelling | doaj-art-8e12fa0e610149fb93d1d7e6520395bb2025-02-03T06:08:48ZengWileyCase Reports in Dermatological Medicine2090-64632090-64712017-01-01201710.1155/2017/93590869359086Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the LiteratureKirsten C. Webb0Magdalena Harasimowicz1Monica Janeczek2Jodi Speiser3James Swan4Rebecca Tung5Department of Dermatology, Loyola University Chicago, Chicago, IL, USAStritch School of Medicine, Loyola University Chicago, Chicago, IL, USAStritch School of Medicine, Loyola University Chicago, Chicago, IL, USADepartment of Pathology, Loyola University Chicago, Chicago, IL, USADepartment of Dermatology, Loyola University Chicago, Chicago, IL, USADepartment of Dermatology, Loyola University Chicago, Chicago, IL, USADasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a morbilliform eruption, skin exfoliation, and skin irritation, pigmentary abnormalities have also been observed, albeit much more rarely. We present the case of a 72-year-old South Asian male with CML who presented with new-onset hypopigmentation of his face and scalp three years after a dose increase of dasatinib therapy, in the setting of newly discovered borderline hypovitaminosis D. Dasatinib and the other TKIs are believed to induce dyschromias via modulation of the c-kit receptor and its associated signaling pathway, which is involved in melanocyte survival, proliferation, and migration.http://dx.doi.org/10.1155/2017/9359086 |
| spellingShingle | Kirsten C. Webb Magdalena Harasimowicz Monica Janeczek Jodi Speiser James Swan Rebecca Tung Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature Case Reports in Dermatological Medicine |
| title | Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature |
| title_full | Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature |
| title_fullStr | Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature |
| title_full_unstemmed | Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature |
| title_short | Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature |
| title_sort | development of asymmetric facial depigmentation in a patient treated with dasatinib with new onset hypovitaminosis d case report and review of the literature |
| url | http://dx.doi.org/10.1155/2017/9359086 |
| work_keys_str_mv | AT kirstencwebb developmentofasymmetricfacialdepigmentationinapatienttreatedwithdasatinibwithnewonsethypovitaminosisdcasereportandreviewoftheliterature AT magdalenaharasimowicz developmentofasymmetricfacialdepigmentationinapatienttreatedwithdasatinibwithnewonsethypovitaminosisdcasereportandreviewoftheliterature AT monicajaneczek developmentofasymmetricfacialdepigmentationinapatienttreatedwithdasatinibwithnewonsethypovitaminosisdcasereportandreviewoftheliterature AT jodispeiser developmentofasymmetricfacialdepigmentationinapatienttreatedwithdasatinibwithnewonsethypovitaminosisdcasereportandreviewoftheliterature AT jamesswan developmentofasymmetricfacialdepigmentationinapatienttreatedwithdasatinibwithnewonsethypovitaminosisdcasereportandreviewoftheliterature AT rebeccatung developmentofasymmetricfacialdepigmentationinapatienttreatedwithdasatinibwithnewonsethypovitaminosisdcasereportandreviewoftheliterature |